Opthea to Participate in Citi 2024 Global Healthcare Conference

Rhea-AI Summary

Opthea (ASX/NASDAQ:OPT), a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases including wet age-related macular degeneration, has announced its participation in the Citi 2024 Global Healthcare Conference. CEO Fred Guerard will conduct one-on-one investor meetings and participate in a panel titled 'Eyes Wide Open on Ophthalmology' on December 5, 2024, at 1:45 PM ET in Miami, Florida. The presentation will be available for viewing on the company's website in the Events & Presentations section.

News Market Reaction

+0.16%

1 alert

+0.16% News Effect

On the day this news was published, OPT gained 0.16%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

MELBOURNE, Australia and PRINCETON, N.J., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Fred Guerard, PharmD, Chief Executive Officer, will host one-on-one meetings with investors and participate in a panel presentation during the Citi 2024 Global Healthcare Conference on December 5, 2024 in Miami, Florida.

Details are as follows:

Panel:	Eyes Wide Open on Ophthalmology
Presenter:	Frederic Guerard, PharmD, CEO, Opthea
Date:	Thursday, December 5, 2024, 1:45 PM ET

The webcast will be accessible on the “Events & Presentations” section of the Company’s website at http://ir.opthea.com/.

About Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.

Authorized for release to ASX by Frederic Guerard, PharmD, CEO

Investor Inquiries
PJ Kelleher 
LifeSci Advisors, LLC 
Email: pkelleher@lifesciadvisors.com
Phone: 617-430-7579 

Media Inquiries 
Silvana Guerci-Lena 
NorthStream Global Partners 
Email: silvana@nsgpllc.com 

Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com
Source: Opthea Limited

FAQ

When is Opthea (OPT) presenting at the Citi 2024 Global Healthcare Conference?

Opthea (OPT) will present at the Citi 2024 Global Healthcare Conference on December 5, 2024, at 1:45 PM ET in Miami, Florida.

What panel is Opthea (OPT) participating in at the Citi Healthcare Conference 2024?

Opthea (OPT) is participating in a panel titled 'Eyes Wide Open on Ophthalmology' at the Citi 2024 Global Healthcare Conference.

Where can investors watch Opthea's (OPT) presentation at the Citi Healthcare Conference?

Investors can access the webcast of Opthea's presentation through the 'Events & Presentations' section of the company's website at ir.opthea.com.

What type of diseases does Opthea (OPT) focus on treating?

Opthea (OPT) focuses on developing therapies for highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD).